John Stephen West, insider at Personalis

John Stephen West Insider Information

CEO of Personalis
Personalis’ CEO, John West, first became involved in DNA sequencing and DNA sequence interpretation in 1982. In the 1980’s, he led the development of an automated DNA sequencing system based on pattern recognition from autoradiographs, and licensed software from the lab of Roger Staden at MRC Cambridge, UK for sequence assembly and analysis. In the 1990’s Mr. West was General Manager and subsequently President of Princeton Instruments, a company focused on low light scientific imaging. This technology was used in a number of fluorescent automated DNA sequencing developments. In 2001 Mr. West joined then market leader Applied Biosystems as Vice President of Genetic Analysis. He was subsequently promoted to VP, DNA Platforms. While at Applied Biosystems Mr. West’s group introduced the model 3730xl Genetic Analyzer. This product became the mainstay of almost every major genome center in the world.

In 2004, Mr. West moved to be CEO of Solexa Ltd, a venture capital backed UK company focused primarily on single-molecule DNA sequencing. Mr. West realized that the company’s recent acquisition of DNA cluster technology could be transformative. In 2005 he led Solexa’s reverse merger into US-based and Nasdaq-listed Lynx Therapeutics, and led two PIPE financings totaling almost $100M. The company introduced its first system in mid-2006. Mr. West negotiated the January 2007 acquisition of Solexa by Illumina, Inc for approximately $600M, and stayed as VP of the DNA sequencing business there into 2008. During this time, Illumina became the world leader in next generation DNA sequencing.

From 2009 through mid-2011 Mr. West served as CEO of ViaCyte, Inc, a company leveraging stem cell technology to develop a diabetes cell therapy.

In late 2009 Mr. West’s family became the first healthy family of four to be sequenced. Their experience  working with the Stanford team on genome interpretation led to the foundation of Personalis.

Mr. West received a BS and MS engineering degrees from MIT, and earned an MBA from the University of Pennsylvania’s Wharton School of Business.

What is John Stephen West's net worth?

The estimated net worth of John Stephen West is at least $1.82 million as of May 16th, 2022. Mr. West owns 382,444 shares of Personalis stock worth more than $1,824,258 as of August 17th. This net worth estimate does not reflect any other investments that Mr. West may own. Additionally, Mr. West receives an annual salary of $1,190,000.00 as CEO at Personalis. Learn More about John Stephen West's net worth.

How old is John Stephen West?

Mr. West is currently 65 years old. There are 4 older executives and no younger executives at Personalis. Learn More on John Stephen West's age.

What is John Stephen West's salary?

As the CEO of Personalis, Inc., Mr. West earned a total compensation package of $4,929,200.00 in 2021. Mr. West earned a salary of $587,500.00, stock awards of $1,061,025.00, options awards of $2,677,575.00, non-equity compensation of $601,600.00, and other compensation of $1,500.00. Learn More on John Stephen West's salary.

How do I contact John Stephen West?

The corporate mailing address for Mr. West and other Personalis executives is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. Personalis can also be reached via phone at (650) 752-1300 and via email at [email protected] Learn More on John Stephen West's contact information.

Has John Stephen West been buying or selling shares of Personalis?

John Stephen West has not been actively trading shares of Personalis in the last ninety days. Most recently, John Stephen West sold 2,408 shares of the business's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $4.86, for a transaction totalling $11,702.88. Following the completion of the sale, the chief executive officer now directly owns 382,444 shares of the company's stock, valued at $1,858,677.84. Learn More on John Stephen West's trading history.

Who are Personalis' active insiders?

Personalis' insider roster includes Richard Chen (Insider), Aaron Tachibana (CFO), and John West (CEO). Learn More on Personalis' active insiders.

Are insiders buying or selling shares of Personalis?

In the last year, Personalis insiders bought shares 1 times. They purchased a total of 48,989 shares worth more than $487,930.44. In the last year, insiders at the sold shares 28 times. They sold a total of 388,980 shares worth more than $5,558,715.87. The most recent insider tranaction occured on July, 28th when insider Richard Chen sold 632 shares worth more than $2,471.12. Insiders at Personalis own 5.8 % of the company. Learn More about insider trades at Personalis.

Information on this page was last updated on 7/28/2022.

John Stephen West Insider Trading History at Personalis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Sell2,408$4.86$11,702.88382,444View SEC Filing Icon  
1/18/2022Sell35,484$11.73$416,227.32View SEC Filing Icon  
12/16/2021Sell97,268$13.42$1,305,336.56View SEC Filing Icon  
11/30/2021Sell100,000$13.65$1,365,000.00View SEC Filing Icon  
11/17/2021Sell2,348$17.04$40,009.92View SEC Filing Icon  
10/12/2021Sell100,000$19.33$1,933,000.00View SEC Filing Icon  
7/8/2021Sell110,000$22.54$2,479,400.00View SEC Filing Icon  
6/8/2021Sell110,000$22.43$2,467,300.00670,520View SEC Filing Icon  
See Full Table

John Stephen West Buying and Selling Activity at Personalis

This chart shows John Stephen West's buying and selling at Personalis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Personalis Company Overview

Personalis logo
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $4.77
Low: $4.77
High: $5.27

50 Day Range

MA: $3.98
Low: $3.27
High: $5.38

2 Week Range

Now: $4.77
Low: $3.13
High: $23.04


360,056 shs

Average Volume

545,981 shs

Market Capitalization

$219.03 million

P/E Ratio


Dividend Yield